Effect of Variceal Eradication on Portal Circulation

Launched by ASSIUT UNIVERSITY · Sep 2, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at how treating varices—enlarged veins that can occur in the esophagus due to liver cirrhosis—affects blood flow in the liver and overall liver health. Specifically, it aims to see if eradicating these varices can improve liver stiffness and certain health scores that help evaluate liver function in patients with cirrhosis.

To participate in this study, you need to be between 18 and 70 years old and have liver cirrhosis classified as Child-Pugh scores A or B, which indicates less severe liver dysfunction. However, if you have a history of certain complications, such as recent significant bleeding from varices or certain types of liver cancer, you won't be eligible. If you join the trial, you'll be monitored closely to see how the treatment affects your condition. It's important to know that this study is not yet recruiting participants, so it will be a little while before you can sign up.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Age between 18 and 70 years old.
• • Patient with documented liver cirrhosis undergoing either primary or secondary prophylactic variceal eradication.
• • Liver cirrhosis with Child-Pugh score A and B.
• Exclusion Criteria:
• • • Age less than 18 years.
• • Have contraindications to computed abdominal CT-angiography (e.g. allergy to all suitable contrast agents, renal failure).
• • Patients with history of recent significant bleeding varices.
• • Previous history of variceal ligation, sclerotherapy, and TIPS operation.
• • Patients with isolated gastric varices.
• • Patients with HCC or other malignancies.
• • End-stage liver disease (Child score more than 9).
• • Patients with malignant portal vein thrombosis.
• • Patients with non-cirrhotic portal hypertension.
• • Patients refuse to participate in the study.